Track topics on Twitter Track topics that are important to you
Individualizing first-line sunitinib was associated with improved response and survival times among patients with metastatic renal cell carcinoma.
Intermittent sunitinib treatment is a feasible first-line approach in patients with renal cell carcinoma (RCC), providing a median progression-free survival duration of 37.6 months. Cyclic re-introduc...
Breaks from active sunitinib treatment for patients with treatment-naive metastatic renal cell carcinoma may be possible without effecting clinical efficacy.
Intermittent treatment with sunitinib is feasible for patients with metastatic renal cell carcinoma and does not seem to compromise its activity, suggest findings from a phase 2 study.
Sunitinib Malate Market: By Disease Pancreatic Neuroendocrine Tumors Kidney Cancer By Region Europe, North America, AsiaPacific Rest of the World RoWForecast 20162021 [Updated: 13092016] Prices from USD $5250
Sunitinib, developed and marketed as Sutent by Pfizer Inc and previously known as SU11248, is a smallmolecule medicine which has to be administered orally and has been proven to be effective in blocki...
Coadministration of diclofenac and sunitinib, tyrosine kinase inhibitor, led to sex-divergent pharmacokinetic drug-drug interaction outcomes. Male and female mice were administered 60 mg/kg PO suniti...
The most efficient sequence of targeted agents for metastatic renal cell carcinoma patients has yet to be identified. Whether the sequence of sorafenib and sunitinib really matters is controversial an...
A novel drug-eluting stent (DES) is required to target vascular smooth muscle cells (SMCs) without harming endothelial cells (ECs). Platelet-derived growth factor (PDGF) is critical for the proliferat...
Two studies presented at the European Society for Medical Oncology 2016 Congress evaluated sunitinib in patients with renal cell carcinomas. The first found that the drug prevents recurrence in patien...
Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of the gastrointestinal tract. In advanced setting and after progression to imatinib, the multi-targeted receptor tyrosine ki...